Tag:
Inovio
Latest Headlines
Latest Headlines
UPDATED: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology
AstraZeneca's big MedImmune subsidiary has nailed down its third pact in 5 days, inking a collaboration with Inovio Pharmaceuticals on a cancer vaccine designed to generate a tumor-specific T cell response. MedImmune is handing over a $27.5 million upfront and up to $700 million in milestones for the deal while agreeing to also cover the research tab.
Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime
Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.
Inovio vs. Feuerstein, Round II: Biotech claims PhII success for VGX-3100
Shares of Inovio Pharmaceuticals jumped about 20% this morning after the biotech said it had hit the mark on the primary endpoint for its mid-stage study of VGX-3100, an experimental therapy designed to eliminate precancerous cervical lesions.
UPDATED: Inovio's DNA-plasmid delivery approach yields potential treatment for chikungunya
Biotech Inovio revealed that all the mice that received its monoclonal antibody targeting chikungunya virus were protected from the disease, raising hopes that the first drug for the condition could be on the horizon.
Roche's cancer immunotherapy quest spurs $422.5M Inovio combo deal
The deal puts Roche--a leader in oncology and a top contender in the immunotherapy field--in the driver's seat on two preclinical therapies that could help marshal a targeted T-cell attack on cancer.
Inovio touts DNA vaccine breakthrough in tiny PoC study
In a small study, an experimental therapeutic cervical cancer vaccine developed by Inovio Pharmaceuticals appeared to spur a surge in T cells, leading the investigators to claim a breakthrough on DNA vaccines.
Inovio shares jump (again) on vax research pact
Shares of Inovio Biomedical jumped again on Monday after the San Diego-based biotech company announced a pact with the NIH Vaccine Research Center to explore new universal influenza jabs and speed
Inovio shares soar again on NIH vax research pact
Shares of Inovio Biomedical jumped again on Monday after the San Diego-based biotech company announced a pact with the NIH Vaccine Research Center to explore new universal influenza jabs and speed
Inovio merging with VGX to work on DNA vaccines
DNA vaccine delivery company Inovio Biomedical is merging with DNA vaccine developer VGX Pharmaceuticals. Inovio is issuing new shares for the deal, which should close before the end of the year. The
